Lancet Impact Factor

Among Medicine, General & Internal journals, The Lancet ranks in the top 1% by impact factor (JCR 2024). This ranking is based on our analysis of 20,449 journals in the Clarivate JCR 2024 database.

The 2021 spike to 202.7 was almost entirely driven by COVID-19 research. The Lancet published several of the most-cited pandemic papers in 2020-2021, including early clinical trial data on COVID-19 treatments and landmark epidemiological studies. As those papers aged out of the 2-year citation window, the IF normalized. The current 88.5 reflects pre-COVID baseline trends with continued growth.

The Lancet's editorial criteria differ from NEJM and JAMA in one important way: global relevance is explicitly stated as an editorial priority, not just implicit.

From Lancet's own author guidelines: the journal prioritizes research with implications beyond high-income countries. A randomized trial conducted entirely in a US tertiary care center, with findings applicable only to that population, is a harder sell than the same trial with a diverse international cohort or explicit analysis of generalizability to lower-resource settings.

This doesn't mean The Lancet only publishes global health research. It publishes landmark clinical trials from high-income settings regularly. But it does mean the framing matters. If your study has relevance to global practice, make that explicit in the cover letter and discussion.

The Lancet's acceptance rate sits below 5% across all submissions:

• ~60-70% desk rejected in 1-2 weeks
• ~15-20% sent to external review
• ~5% ultimately accepted

Desk rejection at The Lancet is predominantly scope-based. Papers that are strong clinical research but lack the "changes practice globally" framing get cut before external review. Papers with regional focus and no attempt to address generalizability are a common desk rejection type.

Among papers that reach external review, the acceptance rate is roughly 20-30%. Getting to external review at The Lancet is itself a meaningful signal.

Lancet revision requests are substantive. First major revisions typically ask for additional analyses, subgroup data, or expanded discussion of generalizability. Budget 2-4 months for a thorough revision response.

The most common published formats in The Lancet:

Large randomized controlled trials: multicenter, international, with primary endpoints that would change clinical practice. Phase 3 trials meeting this bar are the highest-acceptance category.

Systematic reviews and meta-analyses: large-scale reviews of clinical interventions or disease burden. The Cochrane-style systematic review with direct practice implications is a strong fit.

Global burden of disease studies: epidemiological analyses of disease prevalence, incidence, or mortality with country-level or global scope. These form a significant portion of Lancet content.

Health policy analyses: studies examining healthcare systems, access, or outcomes with policy implications. The Lancet publishes more health policy content than any comparable medical journal.

Original research with multinational cohorts: trials or observational studies with international recruitment, improving generalizability.

The JCI of 23.28 is the standout number. It means a Lancet paper is cited 23 times more than the average paper globally when normalized across fields. NEJM's JCI (23.30) is virtually identical, confirming these two journals occupy the same citation tier. The IF difference (88.5 vs 78.5) is less meaningful than the JCI suggests.

The Lancet publishes about 198 articles per year from thousands of submissions. The acceptance filter:

Gets published:

• Large randomized controlled trials (500+ patients) with definitive results
• Global health studies from low- and middle-income countries
• Systematic reviews with meta-analysis on questions that affect clinical practice
• Health policy analyses with data to support recommendations

Gets desk-rejected:

• Single-center observational studies without novel methodology
• Basic science without clear translational or clinical implications
• Case reports (The Lancet publishes these extremely rarely)
• Papers from wealthy-country institutions addressing purely local questions

A Lancet clinical impact and global relevance check can assess whether your paper meets The Lancet's threshold.

In our pre-submission review work with clinical manuscripts targeting The Lancet, three rejection patterns are more consistent than any others.

Wealthy-country studies without international generalizability. The Lancet's editorial criteria state explicitly that papers "from wealthy-country institutions addressing purely local questions" get desk-rejected. The pattern we see: strong RCTs or observational studies conducted entirely in US, UK, or European health systems that do not discuss how findings might apply (or not apply) across different healthcare contexts. This filter is more specific than it sounds. A UK trial of a generic drug for hypertension may pass because the drug is globally available and the treatment question is universally relevant. A US health-systems study of a reimbursement-dependent intervention with no plausible international pathway will not. The manuscript needs either a multi-country study population or a credible discussion of how the result travels across health systems and income levels.

Subspecialty significance without cross-specialty consequence. The Lancet is not a specialty journal running at flagship IF. Papers that are important within one subspecialty, an oncology biomarker, a procedural technique improvement in surgery, an immune subset finding in rheumatology, face rejection if the finding does not illuminate something that affects clinical practice or policy beyond that subspecialty. The Lancet's 88.5 IF is driven by general-medicine and global-health readership; subspecialty papers that belong in The Lancet Oncology, The Lancet Neurology, or a standalone specialty journal are redirected even when the science is strong. The deciding editorial question is whether a general internist in a middle-income country would change patient management based on the result.

Incremental evidence on already-settled clinical questions. Confirmatory meta-analyses, trials refining rather than shifting practice, and studies that add nuance to an established guideline without changing its core recommendation are rejected at the desk. SciRev author reports note a typical Lancet desk rejection takes under two weeks, with feedback citing "insufficient global scope" or "does not advance current clinical practice." The bar is transformation of how the clinical question is answered, not contribution to an ongoing literature. If the primary claim is "our data confirm what previous trials have already shown, with better precision," The Lancet will return the manuscript.

The Lancet's Scopus profile is as strong as its JCR numbers suggest. Its CiteScore of 87.6 captures four years of citation data and confirms extraordinary citation intensity. The SJR of 12.113 is prestige-weighted, meaning The Lancet isn't just cited frequently, it's cited by other top-tier medical journals. The SNIP of 22.724 is one of the highest in all of medicine, indicating that even after normalizing for field citation rates, The Lancet's impact is exceptional. For authors at institutions that use Scopus-based evaluation, these numbers reinforce what the JCR already shows: The Lancet ranks among the most influential journals in the world.